Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
After two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy. Increased evidence is demonstrating the efficacy of PD-L1/PD1 inhibition thera...
Main Authors: | Wei-Bo Yu, Jian-Yu Rao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-09-01
|
Series: | Chronic Diseases and Translational Medicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095882X19300684 |
Similar Items
-
Expression of programmed death ligand 1 (PD-L1) in urothelial bladder carcinoma (immunohistochemical and histopathological study)
by: Nadia Ahmed Abd El-Moeze, et al.
Published: (2021-06-01) -
Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
by: Pei-Fei Liao, et al.
Published: (2023-11-01) -
Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
by: Nam-Hui Yim, et al.
Published: (2020-04-01) -
Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
by: Otgontuya Ganbaatar, et al.
Published: (2021-12-01) -
Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients
by: Eman Eissa, et al.
Published: (2022-01-01)